Oramed Pharmaceuticals (NASDAQ:ORMP – Get Free Report) and TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.
Profitability
This table compares Oramed Pharmaceuticals and TriSalus Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Oramed Pharmaceuticals | N/A | -5.57% | -5.22% |
| TriSalus Life Sciences | -98.45% | N/A | -111.88% |
Institutional & Insider Ownership
12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are owned by institutional investors. 17.8% of Oramed Pharmaceuticals shares are owned by company insiders. Comparatively, 27.5% of TriSalus Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Oramed Pharmaceuticals | $1.34 million | 101.28 | -$19.06 million | $1.26 | 2.71 |
| TriSalus Life Sciences | $29.43 million | 8.57 | -$30.05 million | ($2.02) | -2.50 |
Oramed Pharmaceuticals has higher earnings, but lower revenue than TriSalus Life Sciences. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Oramed Pharmaceuticals has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500. Comparatively, TriSalus Life Sciences has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings for Oramed Pharmaceuticals and TriSalus Life Sciences, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Oramed Pharmaceuticals | 0 | 1 | 0 | 0 | 2.00 |
| TriSalus Life Sciences | 1 | 1 | 2 | 0 | 2.25 |
TriSalus Life Sciences has a consensus price target of $11.00, indicating a potential upside of 117.82%. Given TriSalus Life Sciences’ stronger consensus rating and higher possible upside, analysts plainly believe TriSalus Life Sciences is more favorable than Oramed Pharmaceuticals.
Summary
Oramed Pharmaceuticals beats TriSalus Life Sciences on 8 of the 14 factors compared between the two stocks.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.
About TriSalus Life Sciences
TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
